Clinical safety and efficacy of neoadjuvant combination chemotherapy of tranilast in advanced esophageal squamous cell carcinoma: Phase I/II study (TNAC) was written by Shiozaki, Atsushi;Kudou, Michihiro;Fujiwara, Hitoshi;Konishi, Hirotaka;Shimizu, Hiroki;Arita, Tomohiro;Kosuga, Toshiyuki;Yamamoto, Yusuke;Morimura, Ryo;Ikoma, Hisashi;Kuriu, Yoshiaki;Kubota, Takeshi;Okamoto, Kazuma;Otsuji, Eigo. And the article was included in Medicine (Philadelphia, PA, United States) in 2020.SDS of cas: 53902-12-8 This article mentions the following:
Transient receptor potential vanilloid 2 (TRPV2) was previously shown to play an important role in the maintenance of cancer stem cells, and its specific inhibitor, tranilast, also has potential as a targeted therapeutic agent for esophageal squamous cell carcinoma (ESCC). The present study is being conducted to confirm the safety and efficacy of the addnl. use of tranilast with conventional preoperative adjuvant chemotherapy for patients with advanced ESCC. Between 56 and 59 patients aged between 20 and 74 years with clin. diagnosed Stage II or Stage III ESCC will be enrolled. Eligible patients will receive preoperative adjuvant chemotherapy, 2 cycles of combination therapy with cisplatin, 5-fluorouracil, and tranilast. Recruitment started in Nov. 2019, with the final follow-up being planned for March 2029. One subject has been enrolled since Oct. 21, 2020. The pathol. therapeutic effect is the primary endpoint. The objective response rate, safety of preoperative adjuvant chemotherapy, recurrence-free survival (RFS), and overall survival (OS) are the secondary endpoints. RFS and OS will be calculated as the time from surgery to first recurrence and all-cause death, resp. This protocol has been approved by the Institutional Review Boards of Kyoto Prefectural University of Medicine and all participating hospitals in August 30, 2019 (Number: CRB5180001). Written informed consent will be obtained from all patients before their registration, which is in accordance with the Declaration of Helsinki. The results of the present study will be disseminated via publication in peer-reviewed journals. In the experiment, the researchers used many compounds, for example, 2-(3-(3,4-Dimethoxyphenyl)acrylamido)benzoic acid (cas: 53902-12-8SDS of cas: 53902-12-8).
2-(3-(3,4-Dimethoxyphenyl)acrylamido)benzoic acid (cas: 53902-12-8) belongs to amides. Amides include many other important biological compounds, as well as many drugs like paracetamol, penicillin and LSD. Low-molecular-weight amides, such as dimethylformamide, are common solvents. Amides can be recrystallised from large quantities of water, ethanol, ethanol/ether, aqueous ethanol, chloroform/toluene, chloroform or acetic acid. The likely impurities are the parent acids or the alkyl esters from which they have been made. The former can be removed by thorough washing with aqueous ammonia followed by recrystallisation, whereas elimination of the latter is by trituration or recrystallisation from an organic solvent.SDS of cas: 53902-12-8
Referemce:
Amide – Wikipedia,
Amide – an overview | ScienceDirect Topics